AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26854123
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy (continuation phase)
Trial: 26854123
Drug: MDI to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI to pump therapy (continuation phase)
Trial: 26854123
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy and MDI
Trial: 24424357
Drug: G‐CSF (Filgrastim,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (Filgrastim, Amgen, 300 μg/1.0 mL)
Trial: 14663604
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (prednisolone, hydroxyethyl starch, pentoxifylin)
Trial: 14663604
Drug: Fibrinogen/LDL-apheresis in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen/LDL-apheresis in patients with plasma fibrinogen >295 mg/dl
Trial: 14663604
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy in patients with plasma fibrinogen >295 mg/dl
Trial: 27090097
Drug: Single session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session Brief Intervention/Referral to Treatment (BI/RT)
Trial: 27090097
Drug: Multi-session Brief
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-session Brief Intervention/Referral to Treatment (BI/RT+)
Trial: 25242204
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (2×500 mg/day)
Trial: 22897461
Drug: Rosuvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin monotherapy 40 mg/day (R group)
Trial: 22897461
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group)
Trial: 22897461
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/day combined with ω-3 fatty acids 2 g/day (Rω group)
Trial: 17033631
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rhEPO) 40,000 IU weekly intravenous infusion for 12 weeks
Trial: 9607691
Drug: 35 microg
RxNorm normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 microg ethinyloestradiol + 2 mg cyproterone acetate for 3 months
Trial: 8550255
Drug: Pre-exercise glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exercise glucose polymer (G) and placebo during exercise (G/P)
Trial: 8550255
Drug: Glucose polymer
RxNorm normalized name: glucose polymers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose polymer pre-exercise and during exercise (G/G)
Trial: 1965645
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg cicletanine
Trial: 1965645
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg cicletanine
Trial: 82784
Drug: myo-inositol, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myo-inositol, 500 mg twice a day
Trial: 30745383
Drug: Oxfendazole (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxfendazole (0.5, 1, 3, 7.5, 15, 30, or 60 mg/kg body weight)
Trial: 28143430
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen (10 mg/kg)
Trial: 25818379
Drug: Indication-based off-label
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indication-based off-label medication order scenarios with lower relative expert power
Trial: 25818379
Drug: Indication-based off-label
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indication-based off-label medication order scenarios with less appropriate prescriptions
Trial: 25818379
Drug: Indication-based off-label
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indication-based off-label medication order scenarios
Trial: 21926932
Drug: Tualang honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tualang honey (20 g/d)
Trial: 21926932
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin therapy (Femoston 1/5)
Trial: 17018340
Drug: Cardiac contractility
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac contractility modulation signals (n = 25, treatment group)
Trial: 1286044
Drug: Cisplatin (chemotherapy)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (chemotherapy)
Trial: 3702214
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (1.6 g/kg body wt)
Trial: 3702214
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (0.8 g/kg body wt)
Trial: 27622453
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg every 12 h for 48 h after an initial preoperative dose of parecoxib 40 mg
Trial: 27622453
Drug: Saline every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline every 12 h for 48 h after an initial preoperative dose of saline
Trial: 22428845
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta (IFNβ) treatment
Trial: 20660592
Drug: Self-medication for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication for STI symptoms
Trial: 14984518
Drug: s(+)-ketamine and
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s(+)-ketamine and morphine
Trial: 14984518
Drug: saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline and morphine
Trial: 14564686
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/d and MPA 2.5 mg/d
Trial: 14564686
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/d
Trial: 8996159
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) administered as a 3-hour infusion at dosages of 100 to 250 mg/m2
Trial: 8996159
Drug: Carboplatin (C)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (C) administered over 30 minutes at dosages of 300 to 400 mg/m2
Trial: 8996159
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) and Carboplatin (C) administered in different sequences
Trial: 8996159
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) at doses < 175 mg/m2
Trial: 8996159
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) at doses >= 175 mg/m2
Trial: 8996159
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) with P‐T > or = 0.1 mumol/L for < 15 hours
Trial: 8996159
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) with P‐T > or = 0.1 mumol/L for >= 15 hours
Trial: 2441152
Drug: Diuretic (frusemide)
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (frusemide)
Trial: 29948021
Drug: Sirolimus with
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus with Metformin (Arm A)
Trial: 26996929
Drug: Infection requiring
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infection requiring antibiotics before discharge
Trial: 19021487
Drug: Outlook intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outlook intervention (discussions of end-of-life preparation and completion)
Trial: 11019371
Drug: Diethylstilbestrol diphosphate
RxNorm normalized name: Diethylstilbestrol Diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol diphosphate (DES-P) 300 mg daily for 2 weeks
Trial: 11019371
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) 100 mg daily for 2 weeks
Trial: 31952501
Drug: Galcanezumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab (both doses)
Trial: 25619411
Drug: NLFU +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLFU + SOC (non-contact low-frequency ultrasound therapy combined with standard of care)
Trial: 22226517
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with capecitabine (1000 mg/m² twice daily on days 1 to 14 of each cycle) plus oxaliplatin (130 mg/m² on day 1 of each cycle) for 6 months
Trial: 22226517
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with capecitabine plus oxaliplatin
Trial: 18719041
Drug: Combination antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antipsychotic prescribing (CAP)
Trial: 17230206
Drug: Granulocyte-colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony-stimulating factor (G-CSF) at a subcutaneous daily dose of 10 microg/kg for 5 days
Trial: 17230206
Drug: Granulocyte-colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony-stimulating factor (G-CSF)
Trial: 12162586
Drug: Betaxolol 0.5%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.5%, Non-selective topical beta receptor blockers, Latanoprost 0.005% (in glaucoma patients)
Trial: 3203067
Drug: 0.8 of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 of the minimal erythema dose (MED) of UVB for 8 weeks
Trial: 3203067
Drug: 0.4 of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 of the minimal erythema dose (MED) of UVB for 8 weeks
Trial: 27179257
Drug: Traditional clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional clinic-based therapy + computer-based program (Rannan)
Trial: 27179257
Drug: Traditional clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional clinic-based therapy
Trial: 25330012
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy in group I
Trial: 20401474
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg per week)
Trial: 20401474
Drug: Bevacizumab (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (2.5 mg/kg per week)
Trial: 20401474
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg per week) in renal cell carcinoma patients
Trial: 20401474
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg per week) in breast cancer patients
Trial: 15327040
Drug: Cannabis extract
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis extract (2.5 mg THC and 0.9 mg CBD), dosage escalated from 15 to 30 mg THC over 14 days.
Trial: 2107780
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous prostacyclin (epoprostenol)
Trial: 2107780
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (anticoagulants, oral vasodilators, and diuretics)
Trial: 2107780
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous prostacyclin (epoprostenol) for up to 18 months
Trial: 28189429
Drug: Current regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current regular aspirin (>3 tablets/week)
Trial: 28189429
Drug: Past regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past regular aspirin
Trial: 28189429
Drug: Current postdiagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current postdiagnostic aspirin
Trial: 25431855
Drug: Digital media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital media application on mobile phones showing inhalation therapy steps
Trial: 23545102
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy plus 10 sessions of parasacral transcutaneous electrical neural stimulation (20 minutes, 10 Hz, 700 μs pulse, intensity based on sensitivity threshold, 3 times weekly for 10 sessions)
Trial: 23545102
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (control group)
Trial: 21419290
Drug: Buccal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal plus palatal infiltration (1.8 mL buccal + 0.5 mL palatal of 2% lidocaine with 1:100,000 epinephrine)
Trial: 21419290
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 9121505
Drug: Cyclosporine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (5 mg/kg/day) for 7 months
Trial: 3128054
Drug: Intravenous indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous indomethacin infusion (75 mg/10 h)
Trial: 31821065
Drug: BEP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEP treatment (bleomycin‐etoposide‐cisplatin; n = 1,819)
Trial: 28520618
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus modified directly administered antiretroviral therapy (intervention)
Trial: 28520618
Drug: Atazanavir hair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir hair concentration <2.35 ng/mg
Trial: 28520618
Drug: Atazanavir hair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir hair concentration >2.35 ng/mg
Trial: 25600198
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections with no antibiotic use
Trial: 25600198
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections with preinjection antibiotics only
Trial: 25600198
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections with postinjection antibiotics only
Trial: 25600198
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections with preinjection and postinjection antibiotics
Trial: 19764942
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a 5-grass pollen mixture, ultra-rush titration with doses of 30, 90, 150, and 300 IR every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons.
Trial: 12174058
Drug: Topical arnica
RxNorm normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical arnica gel (applied twice a day for 2 weeks prior to laser treatment)
Trial: 12174058
Drug: Topical arnica
RxNorm normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical arnica gel (applied twice a day for 2 weeks after laser treatment)
Trial: 12174058
Drug: Vehicle (applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (applied twice a day for 2 weeks prior to laser treatment)
Trial: 12174058
Drug: Vehicle (applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (applied twice a day for 2 weeks after laser treatment)
Trial: 7658007
Drug: CVC bandage
RxNorm normalized name: New-Skin Liquid Bandage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC bandage changed twice a week (TAW)
Trial: 141326
Drug: Oral estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estramustine phosphate
Trial: 30543311
Drug: Single mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single mass drug administration of azithromycin
Trial: 9690973
Drug: Sertindole (12-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole (12-24 mg/day)
Trial: 12464464
Drug: Risperidone (4-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4-10 mg/day)
Trial: 8986513
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 16 weeks
Trial: 8986513
Drug: Self-treatment manual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment manual followed by up to 8 weeks of CBT (sequential group)
Trial: 8375517
Drug: Vaginal ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ultrasound and blood samples for hormone parameters between 20 and 30 days after conception
Trial: 3739879
Drug: Propranolol, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 80 mg orally
Trial: 3739879
Drug: Diltiazem, 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 90 mg orally
Trial: 3739879
Drug: Nifedipine, 20
RxNorm normalized name: Nifedipine, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 20 mg orally
Trial: 30028245
Drug: Soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy milk (240 ml daily)
Trial: 30846916
Drug: Scapulothoracic mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scapulothoracic mobilization + Physical Therapy
Trial: 20617290
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of ascorbic acid and 400 IU of alpha-tocopherol (Tx1)
Trial: 20617290
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of ascorbic acid and 400 IU of alpha-tocopherol (Tx2)
Trial: 18595465
Drug: Synbiotics (Normoflorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (Normoflorin B and Normoflorin L)
Trial: 11386492
Drug: Nefazodone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (400 mg/day)
Trial: 3058014
Drug: Verapamil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil administered three times daily (t.i.d.)
Trial: 3058014
Drug: Verapamil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil administered twice daily (b.i.d.)
Trial: 28050917
Drug: Caffeine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4 mg.kg‐1, capsule)
Trial: 18283068
Drug: Cyst(e)ine intake
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyst(e)ine intake <18 mg/kg per day
Trial: 17082779
Drug: Standard remission-induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard remission-induction therapy (idarubicin plus cytarabine)
Trial: 9181158
Drug: Intravenous phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phentolamine (0.5 mg/kg over 30 min)
Trial: 8344801
Drug: Myopia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myopia treatment
Trial: 2870010
Drug: Terbutaline (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.25 mg injected subcutaneously)
Trial: 2870010
Drug: Metaproterenol (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (inhaled via metered dose inhaler)
Trial: 21084039
Drug: Subcutaneous ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous ustekinumab
Trial: 10489821
Drug: Repeated episodes
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated episodes of fever and antibiotic treatment in early life
Trial: 10489821
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of fever episodes and antibiotic courses in asthmatic children